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OBJECTIVES The purpose of this study was to investigate the significance of the possible negative
interaction between aspirin and angiotensin-converting enzyme (ACE) inhibitors.
BACKGROUND Several provocative reports have recently suggested that aspirin is unsafe in patients with heart
failure and has negative interaction with ACE inhibitors that might attenuate their beneficial
effects upon survival.
METHODS We analyzed mortality data of 11,575 patients with coronary artery disease screened for the
Bezafibrate Infarction Prevention trial. A total of 1,247 patients (11%) were treated with
ACE inhibitors. Of them, 618 patients (50%) used aspirin.
RESULTS Five-year mortality was lower among patients on ACE inhibitors and aspirin than patients on
ACE inhibitors without aspirin (19% vs. 27%; p , 0.001). After adjusting for confounders,
treatment with aspirin and ACE inhibitors remained associated with lower mortality risk than
using ACE inhibitors only (relative risk [RR] 5 0.71; 95% confidence interval [CI] 5 0.56
to 0.91). Subgroup analysis of 464 patients with congestive heart failure treated with ACE
inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin. Although
clinical characteristics and therapy were similar, patients taking aspirin experienced lower
mortality than patients who did not (24% vs. 34%; p 5 0.001). After adjustment, treatment
with aspirin was still associated with lower mortality (RR 5 0.70; 95% CI 5 0.49 to 0.99).
CONCLUSIONS Among coronary artery disease patients with and without heart failure who are treated with
ACE inhibitors, the use of aspirin was associated with lower mortality than treatment without
aspirin. Our findings contradict the claim that aspirin attenuates the beneficial effect of ACE
inhibitors and supports its use in patients with coronary artery disease treated with ACE
inhibitors. (J Am Coll Cardiol 1999;33:1920–5) © 1999 by the American College of
Cardiology
Both aspirin and angiotensin-converting enzyme (ACE)
inhibitors are widely and concomitantly used in patients
with coronary artery disease. Aspirin is the first line agent in
treatment of acute myocardial infarction and is of proved
value in patients with a wide range of acute and chronic
ischemic syndromes (1,2). Angiotensin-converting enzyme
inhibitors have become “the cornerstone for the treatment
of heart failure” and improve the prognosis in all stages of
heart failure (3,4). The widespread use of aspirin and ACE
inhibitors in patients with coronary artery disease contrib-
utes significantly to reduction in morbidity and mortality
from this common health problem.
However, in a recent provocative article, Cleland et al. (5)
have questioned the safety of aspirin in patients with heart
failure—especially patients who are taking ACE inhibitors.
Furthermore, the investigators of the SOLVD (6), the
CONSENSUS II (7), the GUSTO-I (8) and other studies
(9–12) have reported that aspirin has negative interaction
with ACE inhibitors, and may attenuate their protective
effects upon the hemodynamics and survival of patients with
congestive heart failure or coronary artery disease. The
theoretical basis for this negative interaction is that aspirin
and ACE inhibitors exert their protective effects through a
related prostaglandin-mediated pathway. Angiotensin-
converting enzyme inhibitors promote the release of vaso-
dilatory prostaglandins (11–14). Inhibition of prostaglandin
synthesis with aspirin or other nonsteroidal anti-
inflammatory drugs has been shown to attenuate the acute
vasodilatory effect of ACE inhibition (10–14).
If aspirin does have a negative interaction with ACE
inhibitors, it may affect the clinical practice of treating
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patients with heart failure and coronary artery disease. The
purpose of our study was, therefore, to evaluate the hypoth-
esis that aspirin may attenuate the beneficial effect of ACE
inhibitors on mortality in a large cohort of patients with
coronary artery disease.
METHODS
Patients. The methods of the Bezafibrate Infarction Pre-
vention (BIP) study (15) and the BIP registry were reported
previously (16). In brief, the BIP study (15) was a placebo-
controlled, secondary prevention study, conducted in 18
cardiology departments in Israel with the aim of assessing
the efficacy of the long-term administration of bezafibrate in
the reduction of fatal and nonfatal coronary events in
patients with coronary artery disease. Between February 1,
1990, and October 30, 1992, clinical and laboratory data on
more than 15,000 male and female patients were collected.
For a total of 14,697 patients with an established diagnosis
of coronary artery disease screened for inclusion in the BIP
study, mortality follow-up was available and they consti-
tuted the population in the BIP registry. Medical, historical
and drug intake data were recorded. Our analysis comprised
patients who had been screened but had not been included
in the BIP study (n 5 11,575). Analysis was thereafter
focused on patients treated with ACE inhibitors with and
without aspirin. The use of an ACE inhibitor was according
to the discretion of the treating physician. Neither the dose
of ACE inhibitor nor indication for its use was recorded.
The most frequent daily dose of aspirin that was prescribed
in Israel at that time was 250 mg of coated aspirin.
End points. The main end point studied was mortality
during a mean follow-up of five years. Mortality data on
11,575 of those who were screened who were not included
in the BIP study were obtained by matching the patients’
identification number with their life status in the Israeli
Population Registry after a mean follow-up period of five
years. Death certificates and diagnosis at hospital discharge
were coded using the system described in the ninth edition
of the International Classification of Disease, in which
coronary artery disease is denoted by codes 410 to 424.
Statistical methods. Analysis was carried out according to
the use of ACE inhibitor or aspirin at the screening visit.
Because the interaction between ACE inhibitors and aspirin
may be confined to patients with heart failure, a subgroup
analysis of patients with heart failure was carried out.
Results of continuous variables are reported as mean value 6
SD. The chi-square and Student t tests were used to
determine the significance of differences between propor-
tions and means, respectively. Survival was estimated by the
life table (actuarial) method. The SAS (Cary, North Caro-
lina) software was utilized, specifically the LIFE TEST
procedure. A Cox proportional-hazards model was used to
evaluate the effect of independent predictors on patients’
survival and to estimate the adjusted relative risk (RR) of
mortality associated with aspirin use in patients taking ACE
inhibitors (17). All reported p values are two sided.
RESULTS
Clinical characteristics. Our study included 11,575 pa-
tients with coronary artery disease. At the screening visit,
1,247 patients (11%) were treated with ACE inhibitors.
Analysis was thereafter focused on this subgroup. Fifty
patients were treated with dipyridamole and were excluded
from the analysis. Table 1 shows the characteristics of
patients treated with ACE inhibitors plus aspirin (n 5 618).
The control group consisted of 579 patients who received
ACE inhibitors but did not receive aspirin or other anti-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BIP 5 Bezafibrate Infarction Prevention
CI 5 confidence interval
MI 5 myocardial infarction
RR 5 relative risk
Table 1. Baseline Clinical Characteristics of 1,197 Patients on
Angiotensin-Converting Enzyme Inhibitors With and Without
Aspirin
Characteristic
With
Aspirin
(n 5 618)
Without
Aspirin
(n 5 579) p
Age (mean 6 SD) 61 6 6 yr 61 6 6 yr 0.72
Women 125 (20%) 145 (25%) 0.05
Hypertension 385 (62%) 353 (61%) 0.6
Diabetes 165 (27%) 159 (27%) 0.8
Smoking (past and current) 393 (64%) 337 (58%) 0.06
Angina 329 (53%) 357 (62%) 0.003
Prior MI 519 (84%) 448 (77%) 0.004
Peripheral vascular disease 45 (7%) 29 (5%) 0.10
Stroke 22 (4%) 11 (2%) 0.08
NYHA functional class
I 377 (63%) 318 (56%) 0.15
II 160 (27%) 173 (31%)
III/IV 61 (10%) 70 (13%)
Unknown 20 (3%) 18 (3%)
Drug therapy
Beta-blockers 147 (24%) 115 (20%) 0.10
Digoxin 87 (14%) 111 (19%) 0.02
Calcium channel
blockers
264 (43%) 270 (47%) 0.17
Diuretic drugs 236 (38%) 296 (51%) 0.001
Antiarrhythmic agents 49 (8%) 66 (11%) 0.04
Nitrates 347 (56%) 352 (61%) 0.15
Captopril 459 (74%) 393 (68%) 0.15
Enalapril 159 (26%) 184 (32%) 0.02
Lisonopril 0 (0%) 2 (0%)
Anticoagulants 14 (2%) 38 (7%) 0.001
MI 5 myocardial infarction; NYHA 5 New York Heart Association.
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platelet drugs. Captopril was the ACE inhibitor most
frequently used (74%), followed by enalapril (26%) (Table
1).
The proportion of patients with history of myocardial
infarction (MI) or angina was higher among patients treated
with aspirin and ACE inhibitors, and relatively more
patients in this subgroup were receiving beta-adrenergic
blocking agents. On the other hand, more patients in the
control group took digoxin, diuretics, antiarrhythmic
agents, nitrates and anticoagulants.
Aspirin crossover. The current analysis, like other pro-
spective observations of outcome after use of medications,
relied on a single report of therapy available to us during
screening examination. Although it is not known how many
of the actual patients included in the present analysis
continued on aspirin and for how long, there is an indirect
estimate for drug crossover. These estimates were derived
from experience with the patients enrolled in the clinical
BIP trial proper. Among 3,122 BIP patients, 386 (12%)
took ACE inhibitors at the screening visit. Of them, 245
took aspirin and 141 patients did not. Among 245 patients
on ACE inhibitors and aspirin at the beginning of the
study, 91% of those alive and seen after one year (n 5 219)
were still using aspirin, and this dropped to 83% alive after
five years. Conversely, 141 patients on ACE inhibitors did
not use aspirin at baseline, and among survivors and
examined patients in this group 31% started aspirin by year
1 (n 5 138) and 55% were on aspirin by year 5 of the study.
We believe that such a trend existed in the entire BIP
registry population and reflects the increasing awareness of
the potential benefit of aspirin in patients with ischemic
heart disease.
Mortality. Figure 1 compares the mortality for patients on
ACE inhibitors with and without aspirin. After a mean
follow-up of five years, there were 119 (19%) deaths in the
ACE inhibitors and aspirin group compared with 155
(27%) deaths in the control group (p 5 0.002). Correspond-
ingly, cardiovascular mortality was lower in ACE inhibitors
and aspirin users than nonusers of aspirin: 77 (12%) versus
103 (18%) (p 5 0.01). After adjustment for age, gender
differences between the groups, prevalence of previous MI,
diabetes mellitus, hypertension, angina pectoris and New
York Heart Association functional class the risk of mortality
was lower in aspirin users than nonusers: RR 5 0.71; 95%
confidence interval (CI) 5 0.56 to 0.91. On further adjust-
ment for the above-mentioned characteristics and concom-
itant use of other medications (beta-blockers, nitrates,
calcium channel blocking agents, digoxin and diuretic
drugs) the risk of mortality was still lower in aspirin users:
RR 5 0.83; 95% CI 5 0.65 to 1.06.
Clinical characteristics of patients with heart failure.
Among the patients treated with ACE inhibitors, there
were 464 patients with congestive heart failure, with New
York Heart Association functional class $2. Table 2 shows
the baseline characteristics of these patients with (n 5 221;
48%) and without (n 5 243) concomitant aspirin treatment.
Most of the clinical characteristics of both groups were
similar. However, the proportion of patients who were
receiving diuretic drugs, antiarrhythmic agents and antico-
agulants was higher among patients who did not receive
aspirin.
Mortality in patients with congestive heart failure. Fig-
ure 2 shows the mortality in patients with congestive heart
failure with New York Heart Association functional class
$2 who were receiving ACE inhibitors with and without
Figure 1. Actuarial survival for patients treated with angiotensin-
converting enzyme inhibitors with and without aspirin.
Table 2. Baseline Clinical Characteristics of 464 Patients With
Heart Failure, Functional Class $II on Angiotensin-Converting
Enzyme Inhibitors, With and Without Aspirin
Characteristic
With
Aspirin
(n 5 221)
Without
Aspirin
(n 5 243) p
Age (mean 6 SD) 61 6 7 yr 62 6 6 yr 0.13
Women 46 (21%) 63 (26%) 0.70
Hypertension 134 (61%) 140 (58%) 0.51
Diabetes 78 (35%) 70 (29%) 0.13
Smoking 142 (64%) 146 (60%) 0.40
Angina 175 (79%) 195 (80%) 0.78
Prior MI 185 (84%) 189 (78%) 0.13
Peripheral vascular disease 24 (10%) 17 (7%) 0.25
Stroke 13 (6%) 5 (2%) 0.03
NYHA functional class
II 160 (72%) 173 (71%) 0.72
III/IV 61 (28%) 70 (29%)
Drug therapy
Beta-blockers 51 (23%) 39 (16%) 0.06
Digoxin 47 (21%) 68 (28%) 0.09
Calcium channel
blockers
109 (49%) 120 (49%) 0.99
Diuretic drugs 109 (49%) 158 (65%) 0.001
Antiarrhythmic agents 13 (6%) 29 (12%) 0.02
Nitrates 156 (71%) 172 (71%) 0.96
Anticoagulants 6 (3%) 21 (9%) 0.006
Abbreviations as in Table 1.
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aspirin. After a mean follow-up of five years, there were 52
(24%) deaths in the aspirin group compared with 85 (35%)
deaths in the control group (p 5 0.007). Cardiovascular
mortality was lower in aspirin users than nonusers: 37 (17%)
versus 64 (26%) (p 5 0.01).
After adjustment for the differences between the groups
in age, gender and diabetes mellitus, the RR was 0.62 (95%
CI 0.44 to 0.87). On further adjustment for concomitant
use of other medications (beta-blockers, nitrates, digoxin
and diuretic drugs) the RR for five years’ mortality was 0.70
with a 95% CI 0.49 to 0.99.
DISCUSSION
We have addressed the recent controversy over the safety of
aspirin in heart failure and the possible negative interaction
between aspirin and ACE inhibitors (5–8). The main
finding of our study indicates that among patients with
coronary artery disease who are treated with ACE inhibi-
tors, use of aspirin is associated with improved survival. This
beneficial association was even more marked in patients
with heart failure. Thus, our findings challenge the claim
that aspirin is unsafe in heart failure and may have a
significant antagonistic interaction with ACE inhibitors.
Theoretical basis for the interaction. The hypothetical
basis for the concerns about aspirin safety and the possible
interaction between aspirin and ACE inhibitors is derived
from the observation that aspirin and ACE inhibitors affect
a similar prostaglandin-mediated pathway. The ACE con-
verts angiotensin-I to the active mediator angiotensin-II. In
addition, ACE inactivates inflammatory mediators such as
bradykinin. Therefore, ACE inhibition leads to increased
concentration of bradykinin. Bradykinin activates endothe-
lial B2 kinin receptors in the vascular endothelium to
promote formation of vasodilator prostaglandins, such as
prostacyclin and prostaglandin E2 and increased formation
of nitric oxide (11–14). Prostaglandins formed during ACE
inhibition contribute to the vasodilation and afterload re-
duction in patients with congestive heart failure and coro-
nary artery disease (12–14,18,19). Aspirin, which inhibits
prostaglandin synthesis, might reduce the beneficial effects
of ACE inhibition, may result in vasoconstriction and
reduction in cardiac output and may aggravate heart failure
(8,18,19).
Baur et al. (20) suggested that the additive therapeutic
effect of aspirin on heart failure patients treated with
enalapril is insignificant. They suggested that because ena-
lapril reduces the formation of thromboxane A2 it provides
an independent antithrombotic effect.
Comparison with other studies. The data on the safety of
aspirin in heart failure and on the interaction with ACE
inhibitors are inconclusive. Hall et al. (9) showed in a
randomized controlled trial that 350 mg of aspirin amelio-
rates the beneficial effects of 10 mg of enalapril on systemic
vascular resistance, left ventricular filling pressure, total
pulmonary resistance and cardiac output in severe heart
failure. Guazzi et al. (10) reported that 10 mg of enalapril
twice a day improves alveolar–capillary membrane diffusing
capacity in patients with chronic heart failure and that this
beneficial effect was attenuated by 325 mg of aspirin. Most
recently, Spaulding et al. (18) reported that a single dose of
10 mg of enalapril reduced systemic vascular resistance more
effectively when given in combination with 500 mg of
ticlopidine than with 325 mg of aspirin.
Large clinical trials have also suggested a negative inter-
action between aspirin and ACE inhibitors. In the SOLVD
study (6), enalapril did not improve survival among a sub-
group of patients with heart failure taking aspirin. Nguyen
et al. (7) found a negative interaction between aspirin and
enalapril in MI patients enrolled in the CONSENSUS II
study. They suggested that aspirin and enalapril interaction
increases mortality after acute myocardial infarction (7).
Most recently, a subgroup analysis of diabetic MI patients
enrolled in the GISSI-3 indicated a lesser absolute and
relative benefit from lisonopril in patients treated with
aspirin than patients who were not (21). The GUSTO-I
investigators (8) suggested that among MI survivors without
heart failure, when ACE inhibitors were concurrently used,
aspirin was not associated with reduced one-year mortality.
The latter observation may support the hypothesis that the
anti-ischemic effect of aspirin on patients treated with ACE
inhibitors is reduced because ACE inhibitors already atten-
uate the formation of thromboxane A (20).
Our findings contradict the findings of subgroup analyses
in the SOLVD (6), the CONSENSUS II (7), the
GUSTO-I (8) and the GISSI-3 (21) trials. This may be
partly related to the relatively low dose of aspirin (250 mg)
used in the patient included in the BIP registry. In addition,
differences in the characteristics of the population included
in the BIP registry—patients with chronic ischemic heart
disease—compared with MI patients (CONSENSUS II,
GUSTO-I and GISSI-3) and pure heart failure patients
(SOLVD) may explain the contradictory findings. Our
findings get support from other studies that did not find a
significant negative interaction between aspirin and ACE
Figure 2. Actuarial survival for patients with heart failure (New
York Heart Association class $2) treated with angiotensin-
converting enzyme inhibitors with and without aspirin.
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inhibitors. Jeserich et al. (22) suggested that aspirin and
ACE inhibitors both exerted beneficial effects on
acetylcholine-mediated forearm vasodilation. Baur et al.
(20) found no important interaction between aspirin
(300 mg) and enalapril on hemodynamics or renal function.
Boger et al. (12) reported that low dose of aspirin (100 mg)
does not interfere with the hemodynamic effects of capto-
pril. Furthermore, the most recent report from the Capto-
pril and Thrombolysis Study investigators (23) suggested
that aspirin does not attenuate the beneficial effects of ACE
inhibition after acute MI, but independently reduces left
ventricular dilation in patients after MI. This encouraging
finding may be explained by Alhaddad et al. (24), who
suggested that aspirin increases the patency of the microves-
sels in the infarcted myocardium and enhances the benefit of
late reperfusion on left ventricular remodeling in a rat model
of anterior MI.
Limitations. We are aware of certain limitations of our
study (25). First, we conducted a post hoc analysis on groups
with different characteristics. Although we attempted to
adjust statistically for the differences, we cannot exclude the
influence of indication bias and confounding variables on
patient outcome. Second, we have relied on a single report
of therapy for each patient during a screening examination,
although therapy may undergo several changes during
follow-up. This is a shortcoming of most such observations.
We have an indirect estimate for drug crossover derived
from experience with the patients enrolled in the clinical
BIP trial proper. This trend indicated that more patients
started taking aspirin than those who stopped taking aspi-
rin. We believe that such a trend existed in the entire BIP
registry population and reflects the increasing awareness of
the potential benefit of aspirin in patients with ischemic
heart disease. Thus, the possible crossover between groups
might produce underestimation of the benefit associated
with using aspirin in patients on ACE inhibitors. Finally,
our observation does not rule out a hemodynamic negative
interaction between aspirin and ACE inhibitors. However,
it suggests that if such a negative interaction does exist it
does not affect survival.
Despite these limitations, the results we derived from our
analysis might contribute to the recent discussion on the
safety of aspirin in patients with heart failure and in patients
receiving ACE inhibitors.
Implications and future research. Our observation from
the BIP registry provides support for the benefit of using
aspirin and ACE inhibitors in patients with coronary artery
disease with and without heart failure. The safety of aspirin
in patients with heart failure or patients receiving ACE
inhibitors may be a dose-dependent phenomena (11) or
limited to certain subgroups. Until more data are gathered,
we believe that low dose aspirin (,250 mg) is safe and can
be given with ACE inhibitors to patients with coronary
artery disease and heart failure.
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